Contact Information: For More Information, Contact: James E. Fickenscher CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent, Jr. V.P., IR Auxilium Pharmaceuticals, Inc. (484) 321-5900
Auxilium Pharmaceuticals to Present at the Credit Suisse 18th Annual Global Healthcare Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - November 10, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that executive management will participate in the Credit
Suisse Global Healthcare Conference to be held November 11 - 13, 2009 at
the Arizona Biltmore in Phoenix, Arizona. Mr. Jim Fickenscher, Chief
Financial Officer, is scheduled to present an overview of the Company and
its product pipeline at 8:00 a.m. MST on Friday, November 13, 2009.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has five
projects in clinical development. XIAFLEX™ (collagenase clostridium
histolyticum), formerly referred to as AA4500, has completed phase III
clinical trials for the treatment of Dupuytren's disease, and the biologics
license application is under review at the FDA for the treatment of
Dupuytren's disease. XIAFLEX is in phase IIb of development for the
treatment of Peyronie's disease and is in phase II of development for
treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's
transmucosal film product candidate for the treatment of overactive bladder
(AA4010) and its fentanyl pain product using its transmucosal delivery
system are in phase I of development. The Company is currently seeking a
partner to further develop these product candidates. Auxilium has rights
to additional pain products and products for hormone replacement and
urologic disease using its transmucosal film delivery system. Auxilium
also has options to all indications using XIAFLEX for non-topical
formulations. For additional information, visit http://www.auxilium.com.
Safe Harbor Statement
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Credit Suisse 18th
Annual Global Healthcare Conference and products in development for the
treatment of Dupuytren's contracture, Peyronie's disease and Frozen
Shoulder Syndrome and for pain, hormone replacement and urologic disease.
All statements other than statements of historical facts contained in this
release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including further
evaluation of clinical data, results of clinical trials, decisions by
regulatory authorities as to whether and when to approve drug applications,
and general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries and those
discussed in the Company's Annual Report on Form 10-K for the year ended
December 31, 2008 and the Company's Quarterly Report on Form 10-Q for the
period ended June 30, 2009 under the heading "Risk Factors," which are on
file with the Securities and Exchange Commission (the "SEC") and may be
accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of Auxilium's home page on the Internet at
http://www.Auxilium.com under the heading "Investor Relations -- SEC
Filings." There may be additional risks that Auxilium does not presently
know or that Auxilium currently believes are immaterial which could also
cause actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.